title: German Hodgkin's Lymphoma Study Group trials: lessons from the past and current strategies.
abstract: Over the past decades, Hodgkin's lymphoma has become one of the most curable tumors in adults. This is mainly because of large clinical trials using risk-adapted, highly effective therapy modalities. For a long time, radiation therapy was the standard for treating patients with Hodgkin's lymphoma. Within the past 20 years, management has undergone a paradigm shift from the use of chemotherapy as an adjunct to radiation therapy in advanced-stage disease to combined therapy modalities with chemotherapy and involved-field irradiation in early stages and time- and dose-intensified effective drug regimens in advanced stages. Modern therapeutic strategies aim at reducing therapy-associated acute and late toxicities, while maintaining the highest tumor control. Founded in 1978, the German Hodgkin's Lymphoma Study Group has initiated numerous clinical trials contributing to the high cure rate in all stages of this lymphoma entity. This article gives an overview of the German Hodgkin's Lymphoma Study Group trials and a review of the current treatment strategies.
authors.affiliation: Department of Internal Medicine I, University of Cologne, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Draube
authors.forename: Karolin
authors.initials: K
authors.lastname: Behringer
authors.forename: Volker
authors.initials: V
authors.lastname: Diehl
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005858:Germany; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009367:Neoplasm Staging; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents